Pemvidutide is a synthetic peptide commercialized by Altimmune, with a leading Phase II program in Obesity. According to Globaldata, it is involved in 8 clinical trials, of which 6 were completed, and 2 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Pemvidutides valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Pemvidutide is expected to reach an annual total of $143 mn by 2039 in the US based off GlobalDatas Expiry Model. The drugs revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drugs phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Pemvidutide Overview
Pemvidutide (ALT-801) is under development for the treatment of obesity, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease and type 2 diabetes. The drug candidate is administered subcutaneously. It is a synthetic peptide and is an analogue of oxyntomodulin. The drug candidate targets GLP-1 and glucagon receptor. It is developed based on EuPort technology.
Altimmune Overview
Altimmune, is a biopharmaceutical company that includes the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The companys pipeline products include Pemvidutide (formerly ALT-801), a glucagon receptor to treat metabolic dysfunction that leads to metabolic dysfunction-associated steatohepatitis (MASH). Altimmune operates under the brands NasoVAX, HepTcell, EuPort, Densigen and RespirVec. The company through its subsidiaries operates in Australia, the UK and the US. Altimmune is headquartered in Gaithersburg, Maryland, the US.
The company reported revenues of (US Dollars) US$0.4 million for the fiscal year ended December 2023 (FY2023), compared to a revenue of US$0.1 million in FY2022. The operating loss of the company was US$95.9 million in FY2023, compared to an operating loss of US$87.7 million in FY2022. The net loss of the company was US$88.5 million in FY2023, compared to a net loss of US$84.7 million in FY2022.
For a complete picture of Pemvidutides valuation, buy the drugs risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
